VYNE THERAPEUTICS VYNE 深 沪
等待开盘 08-02 09:30:00 美东时间
0.351
-0.015
-3.99%
华盛通- 最 高0.365
- 今 开0.3436
- 成交量 248.68万股
- 最 低 0.3436
- 昨 收 0.3656
- 总市值 584.94万
- 52周最高 4.30
- 市盈率 静 --
- 换手率 14.92%
- 52周最低 0.3403
- 委 比 -89.02%
- 总股本 1666.49万
- 历史最高 2869.92
- 量 比 0.35
- 振 幅 5.85%
- 历史最低 0.3403
- 每 手 1
- 风险率 0.55%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多HC Wainwright & Co. Downgrades VYNE Therapeutics to Neutral
HC Wainwright & Co. analyst Joseph Pantginis downgrades VYNE Therapeutics (NASDAQ:VYNE) from Buy to Neutral.
07-30 23:20
VYNE Therapeutics Announces Phase 2b Trial With Repibresib Gel In Nonsegmental Vitiligo Did Not Meet Primary Endpoint Or Key Secondary Endpoint of F-VASI50 And F-VASI75
Trial Did Not Meet Primary Endpoint or Key Secondary Endpoint of F-VASI50 and F-VASI75Nominally Statistically Significant Effects Observed in Key Secondary and Exploratory Endpoints of Change from Baseline in F-VASI and
07-30 20:08
VYNE Therapeutics Announces Topline Results from Phase 2b Trial with Repibresib Gel in Nonsegmental Vitiligo
VYNE Therapeutics announced Phase 2b trial results for Repibresib gel in nonsegmental vitiligo. The trial did not meet the primary endpoint of F-VASI50 or key secondary endpoint of F-VASI75. However, the highest dose (3%) showed nominal statistical significance in percent change from baseline in F-VASI (-43.6%) and T-VASI (-28.3%) scores. High vehicle effect and dropout rates impacted results. VYNE will terminate the trial's extension phase and s...
07-30 12:00
VYNE Therapeutics Provides Program Update on Oral BET inhibitor VYN202
VYNE Therapeutics provided an update on its VYN202 program following a clinical hold by the FDA in April. The FDA lifted the hold for female patients on 0.25 mg and 0.5 mg doses in the Phase 1b psoriasis trial, while the 1 mg dose was excluded due to safety concerns. Preliminary data showed improvement in psoriasis symptoms and cytokine levels for VYN202-treated subjects. The company will not enroll new patients in the psoriasis trial and will fo...
07-02 11:45
12 Health Care Stocks Moving In Wednesday's Intraday Session
Gainers Plus Therapeutics (NASDAQ:PSTV) stock increased by 66.2% to $0.31 duri...
06-26 01:06
VYNE Therapeutics Q1 EPS $(0.20) Beats $(0.29) Estimate, Sales $202.00K Beat $50.00K Estimate
VYNE Therapeutics (NASDAQ:VYNE) reported quarterly losses of $(0.20) per share which beat the analyst consensus estimate of $(0.29) by 31.03 percent. This is a 33.33 percent decrease over losses of $(0.15) per share from
05-08 20:06
Why Paymentus Holdings Shares Are Trading Higher By Over 8%; Here Are 20 Stocks Moving Premarket
Shares of Paymentus Holdings, Inc. (NYSE:PAY) rose sharply in today's pre-marke...
03-11 18:55
VYNE Therapeutics Reports Progress in Clinical Trials
Vyne Therapeutics Inc ( ($VYNE) ) has released its Q4 earnings. Here is a break...
03-08 11:57
VYNE Therapeutics Stock: A Deep Dive Into Analyst Perspectives (5 Ratings)
Analysts' ratings for VYNE Therapeutics (NASDAQ:VYNE) over the last quarter var...
03-07 03:02
美股大行评级 | Maxim Group：维持Adeia"买入"评级，目标价从15美元升至17美元
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1099616672362106881.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• Maxim Group：维持Chemomab Therapeutics(CMMB)"买入"评级，目标价从4美元升至7美元</p> <p>• B. Riley证券：维持全球星(GSAT)"买入"评级，目标价从4美元调整至60
02-21 13:48
